Small-molecule inhibitors of anaplastic lymphoma kinase (ALK), antibodies against the NB antigen GD2 and radiolabelled somatostatin analogues [6,7] represent novel targeted strategies, but chemotherapy (CT) continues to be the cornerstone in systemic NB treatment. The gene discussed is ALK; the disease is neuroblastoma.